<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03373786</url>
  </required_header>
  <id_info>
    <org_study_id>RG012-06</org_study_id>
    <nct_id>NCT03373786</nct_id>
  </id_info>
  <brief_title>A Study of RG-012 in Subjects With Alport Syndrome</brief_title>
  <official_title>A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection in Subjects With Alport Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regulus Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regulus Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, multi-center study of the safety, pharmacodynamics, and
      pharmacokinetics of RG-012 administered to subjects with Alport syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, multi-center study of the safety, pharmacodynamics, and pharmacokinetics
      of RG-012 administered to subjects with Alport syndrome. During this open-label study, all
      eligible subjects will receive RG-012. The study consists of two parts (Part A and Part B).
      During Part A, half of the participants will receive a single dose of RG-012 and half will
      receive 4 doses of RG-012 (one dose every other week for 6 weeks). All subjects will undergo
      two renal biopsies, one before and one after receiving RG-012, to assess the effect of RG-012
      on the kidney. After completing Part A, subjects will be able to enter Part B of the study.
      During Part B, all subjects will receive RG-012 every other week for 48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
    <description>Incidence and severity of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of RG-012 on renal microRNA-21 (miR-21)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in miR-21 expression in renal tissue</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameter - Cmax</measure>
    <time_frame>8 weeks</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameter - Tmax</measure>
    <time_frame>8 weeks</time_frame>
    <description>Time to maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameter - AUC</measure>
    <time_frame>8 weeks</time_frame>
    <description>Area under the plasma concentration vs. time curve</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Alport Syndrome</condition>
  <arm_group>
    <arm_group_label>RG-012 Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg/kg RG012 subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RG012 Every Other Week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg/kg RG012 subcutaneous injections every other week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RG012</intervention_name>
    <description>RG012 in 0.3% sodium chloride</description>
    <arm_group_label>RG-012 Single Dose</arm_group_label>
    <arm_group_label>RG012 Every Other Week</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females, ages 18 to 65 years

          2. Confirmed diagnosis of Alport syndrome

          3. eGFR between 40 and 90 mL/min/1.73m2

          4. Proteinuria of at least 300 mg protein/g creatinine

          5. For subjects taking an ACE inhibitor or an ARB, the dosing regimen should be stable
             for at least 30 days prior to screening

          6. Willing to comply with contraception requirements

        Exclusion Criteria:

          1. Causes of chronic kidney disease aside from Alport syndrome (such as diabetic
             nephropathy, hypertensive nephropathy, lupus nephritis, or IgA nephropathy)

          2. End stage renal disease (ESRD) as evidenced by ongoing dialysis therapy or history of
             renal transportation

          3. Any other condition that may pose a risk to the subject's safety and well-being

          4. Female subjects who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Deeg, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Regulus Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Deeg, M.D.</last_name>
    <phone>858-202-6343</phone>
    <email>mdeeg@regulusrx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Ann Melia, M.A.</last_name>
    <phone>858-202-6323</phone>
    <email>lisa_ann_melia@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>J. Scott Overcash, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mohamed El-Shahawy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Apex Research of Riverside</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chao H. Sun, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Nephrology Research</name>
      <address>
        <city>Cypress</city>
        <state>Texas</state>
        <zip>77429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rupi K Chatha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Utah Kidney Research Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Herndon</last_name>
      <phone>801-747-9186</phone>
      <email>ukrinephrology@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sanjiv Anand, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegiance Research Specialists, LLC</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney disease</keyword>
  <keyword>Nephritis</keyword>
  <keyword>Hereditary kidney disease</keyword>
  <keyword>Hereditary nephritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Nephritis, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

